BMO Capital Downgrades Vitae Pharmaceuticals (VTAE) to Market Perform
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
BMO Capital downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Outperform to Market Perform with a price target of $21.00 (from $17.00).
Shares of Vitae Pharmaceuticals closed at $20.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Raises Price Target on ManpowerGroup (MAN) Following 3Q Surprise
- SunTrust Downgrades Everyday Health (EVDY) to Hold
- H.C. Wainwright Downgrades Vertex (VRTX) to Neutral
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!